Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages

  Landolt, Nadia K ^a   Phanuphak, Nittaya ^b,c   Ubolyam, Sasiwimol ^a   Pinyakorn, Suteeraporn ^a   Kerr, Stephen ^a,d   Ahluwalia, Jennisa ^a   Thongpaeng, Parawee ^a   Thammajaruk, Narukjaporn ^a   Cremers, Serge ^e   Thomas, Tiffany ^e   Chaithongwongwatthana, Surasith ^f   Lange, Joep M A ^a,g   Ananworanich, Jintanat ^a,b,c,f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c SEARCH   (Thailand)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e NewYork Presbyterian Hospital   (United States)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; EFAVIRENZ; ETHINYLESTRADIOL; ETONOGESTREL; NEVIRAPINE;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; BENZOXAZINES; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PROSPECTIVE STUDIES;

EID: 84901489674     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000134     Document Type: Letter

References (24)

1. WHO. Hormonal contraception and HIV. Technical statement 2012. Available at: http://whqlibdoc.who.int/hq/2012/WHO-RHR-12.08-eng.pdf. Accessed July 18, 2012.
2. Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004;32:1209-1212. (Pubitemid 39410903)
3. Korhonen T, Tolonen A, Uusitalo J, et al. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005;60:69-75. (Pubitemid 40942783)
4. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-Infected women. J Acquir Immune Defic Syndr. 2002;29:471-477. (Pubitemid 34456338)
5. Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr. 2011;58:e40-e43.
6. Joshi AS, Fiske WD, Benedek IH, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. Conf Retrovir Oppor Infect. 1998. Abstract no. 348. Available at: http://www.aegis.org/DisplayContent/?SectionID=327474. Accessed March 14, 2014.
7. Carten ML, Kiser JJ, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012;2012:137192.
8. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16:149-156.
9. Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr. 2013;62:534-539.
10. McClamrock HD, Adashi EY. Pharmacokinetics of desogestrel. Am J Obstet Gynecol. 1993; 168:1021-1028. (Pubitemid 23094297)
11. MARVELON® 150/30 tablets. Available at: http://home.intekom.com/ pharm/donmed/marvelon.html. Accessed August 1, 2012.
12. Kaufman JM, Thiery M, Vermeulen A. Plasma levels of ethinylestradiol (EE2) during cyclic treatment with combined oral contraceptives. Contraception. 1981;24:589-602. (Pubitemid 12240146)
13. Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol. 2012;207:39.e1-e6.
14. Thomas T, Petrie K, Shim J, et al. A UPLCMS/MS method for therapeutic drug monitoring of etonogestrel. Ther Drug Monit. 2013; 35:844-848.
15. Fotherby K, Akpoviroro J, Abdel-Rahman HA, et al. Pharmacokinetics of ethynyloestradiol in women for different populations. Contraception. 1981;23:487-496. (Pubitemid 11061689)
16. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3Amediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294. (Pubitemid 35284253)
17. Yamaori S, Yamazaki H, Iwano S, et al. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of coregulation of the expression of CYP3A in Japanese livers. Xenobiotica. 2005;35:69-83. (Pubitemid 40459218)
18. Israel R, Mishell DR Jr, Stone SC, et al. Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol. 1972;112:1043-1046.
19. Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag. 2008;4:905-911.
20. Rosenberg MJ, Meyers A, Roy V, et al. Efficacy, cycle control, and side effects of low- and lowerdose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 1999;60:321-329. (Pubitemid 30133220)
21. Leticee N, Viard JP, Yamgnane A, et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85:425-427.
22. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care. 2007;33:277-278. (Pubitemid 47597636)
23. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009;10:1323-1339.
24. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277-283. (Pubitemid 38523308)